Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

American Heart Journal

Volumn 155, Issue 3, 2008, Pages 499.e9-499.e16

  Rosenson, Robert S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FENOFIBRATE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 39149145837     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.12.012     Document Type: Article

References (36)

1. Macphee C.H., Moores K.E., Boyd H.F., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338 Pt 2 (1999) 479-487
2. Subbanagounder G., Leitinger N., Schwenke D.C., et al. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol 20 (2000) 2248-2254
3. Subbanagounder G., Wong J.W., Lee H., et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem 277 (2002) 7271-7281
4. Rizos E., Tambaki A.P., Gazi I., et al. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 203-209
5. Noto H., Chitkara P., and Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications 20 (2006) 343-348
6. Delerive P., De Bosscher K., Besnard S., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274 (1999) 32048-32054
7. Muhlestein J.B., May H.T., Jensen J., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48 (2006) 396-401
8. Tsimihodimos V., Kakafiki A., Tambaki A.P., et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 44 (2003) 927-934
9. Tsimihodimos V., Kostoula A., Kakafika A., et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 9 (2004) 27-33
10. 2 in obese patients with metabolic syndrome. Atherosclerosis 193 (2007) 428-437
11. Rosenson R.S., Wolff D.A., Huskin A.L., et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30 (2007) 1945-1951
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
13. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
14. Kaikkonen J., Tuomainen T.P., Nyyssonen K., et al. C18 hydroxy fatty acids as markers of lipid peroxidation ex vivo and in vivo. Scand J Clin Lab Invest 64 (2004) 457-468
15. Caslake M.J., Packard C.J., Suckling K.E., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
16. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
17. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
18. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
19. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
20. Tselepis A.D., Dentan C., Karabina S.A., et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 15 (1995) 1764-1773
21. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc 82 (2007) 159-165
22. Stafforini D.M., Tjoelker L.W., McCormick S.P., et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274 (1999) 7018-7024
23. Benitez S., Sanchez-Quesada J.L., Ribas V., et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 108 (2003) 92-96
24. Nordestgaard B.G., and Zilversmit D.B. Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits. Differences in intimal clearance explained by size differences. Arteriosclerosis 9 (1989) 176-183
25. Sanchez-Quesada J.L., Camacho M., Anton R., et al. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 66 (2003) 261-270
26. Tribble D.L., Holl L.G., Wood P.D., et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93 (1992) 189-199
27. Hodis H.N., Kramsch D.M., Avogaro P., et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein. J Lipid Res 35 (1994) 669-677
28. Sevanian A., Hwang J., Hodis H., et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 16 (1996) 784-793
29. Takahara N., Kashiwagi A., Maegawa H., et al. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 45 (1996) 559-564
30. 2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol 6 (2006) 154-161
31. 2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 505 (2001) 357-363
32. 2 in leukocyte activation and inflammatory responses. Atherosclerosis 191 (2007) 54-62
33. 2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51 (2005) 2264-2273
34. Tambaki A.P., Rizos E., Tsimihodimos V., et al. Effects of anti-hypertensive and hypolipidemic drugs on plasma and high density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther 9 (2004) 91-95
35. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
36. Rosenson R.S. Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Curr Atheroscler Rep 8 (2006) 219-222